Randomized Trial Links Time of Day to Immunotherapy Success - PubMed
3 months ago
- #immunotherapy
- #non-small cell lung cancer
- #circadian biology
- Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer.
- First randomized trial of immunotherapy timing links time of day to treatment success.
- Results support aligning treatment with circadian biology to improve cancer outcomes.